Compare Heron Therapeutics Inc (HRTX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Wipro Limited — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Wipro Limited is far larger — about 221× Heron Therapeutics Inc's market cap, and Wipro Limited pays a 5.19% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Wipro Limited for 41 Days on average.
| HRTX | WIT | |
|---|---|---|
Market Cap | $74.04M | $16.36B |
Volume | 3,668,095 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $1.49 | $3.06 |
52-Week Low | $0.27 | $1.61 |
Typical Hold Time | 35 Days | 41 Days |
Enterprise Value | $180.78M | $14.47B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent AI productivity gains. The company reported $890.88B revenue for 2025 with solid 13.92% net margins and reasonable valuation (P/E 12.78). Recent quarters show earnings misses, but cash flow remains strong at $25.02B. Analyst sentiment is mixed with only 19% buy ratings.
Wipro faces execution risks amid competitive IT services market, though AI initiatives show promise. The stock offers value pricing but requires earnings acceleration to justify higher multiples. Near-term performance depends on client spending recovery and AI deployment success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
